🧬 Doug Drysdale - Cybin - Part 4 | The Challenges of Running a Public Company | Transforming Psychiatric Treatments Through Psychedelic Compounds | Developing Breakthrough Therapies in Depression & Anxiety

Part 4 of 4.

My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics.

Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.